Your browser is no longer supported. Please, upgrade your browser.
Settings
PETX Aratana Therapeutics, Inc. daily Stock Chart
PETX [NASD]
Aratana Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.45 Insider Own12.10% Shs Outstand42.45M Perf Week2.50%
Market Cap243.22M Forward P/E- EPS next Y-0.45 Insider Trans-16.44% Shs Float41.92M Perf Month-16.47%
Income-55.20M PEG- EPS next Q-0.23 Inst Own75.60% Short Float7.07% Perf Quarter-8.03%
Sales15.40M P/S15.79 EPS this Y61.10% Inst Trans1.19% Short Ratio7.13 Perf Half Y-15.49%
Book/sh2.21 P/B2.59 EPS next Y56.30% ROA-37.90% Target Price9.30 Perf Year-26.25%
Cash/sh1.66 P/C3.46 EPS next 5Y15.00% ROE-60.50% 52W Range4.97 - 8.63 Perf YTD-20.19%
Dividend- P/FCF- EPS past 5Y-42.90% ROI-23.60% 52W High-33.60% Beta3.39
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin17.40% 52W Low15.29% ATR0.33
Employees85 Current Ratio3.40 Sales Q/Q15307.50% Oper. Margin- RSI (14)43.66 Volatility4.73% 5.79%
OptionableYes Debt/Eq0.39 EPS Q/Q44.80% Profit Margin- Rel Volume1.18 Prev Close5.58
ShortableYes LT Debt/Eq0.26 EarningsFeb 01 AMC Payout- Avg Volume415.52K Price5.73
Recom1.80 SMA20-6.02% SMA50-8.28% SMA200-7.42% Volume489,938 Change2.69%
Nov-17-17Initiated H.C. Wainwright Buy $10
Aug-25-17Reiterated Lake Street Buy $15 → $10
May-10-17Reiterated Stifel Buy $8 → $7
Sep-06-16Resumed Lake Street Buy $15
Aug-19-16Resumed Jefferies Buy
Mar-16-16Reiterated Stifel Buy $12 → $11
Feb-04-16Initiated Credit Suisse Outperform
Nov-30-15Reiterated Barclays Overweight $30 → $15
Sep-25-15Downgrade Craig Hallum Buy → Hold
Jul-29-15Initiated Lake Street Buy $28
Feb-25-15Reiterated Stifel Buy $19 → $23
May-14-14Reiterated Stifel Buy $30 → $22
Feb-10-14Initiated Barclays Overweight $30
Oct-25-13Reiterated Stifel Buy $13 → $33
Jul-25-13Initiated William Blair Outperform
Jul-23-13Initiated William Blair Outperform
Jul-22-13Initiated Stifel Buy $13
Dec-15-17 04:15PM  Aratana Therapeutics Announces Study Results for AT-016 PR Newswire
Dec-08-17 01:19PM  ETFs with exposure to Aratana Therapeutics, Inc. : December 8, 2017 Capital Cube
Nov-28-17 07:08PM  Aratana cancels stock offering after shares plunge MarketWatch -18.95%
06:56PM  Aratana Therapeutics, Inc. Announces Termination of Offering of Common Stock PR Newswire
04:30PM  Why Momo, Aratana Therapeutics, and Sea Limited Slumped Today Motley Fool
01:04PM  Why Aratana Therapeutics Inc. Is Tanking Today Motley Fool
Nov-27-17 04:10PM  Aratana Therapeutics, Inc. Announces Proposed Public Offering PR Newswire
Nov-24-17 10:49AM  ETFs with exposure to Aratana Therapeutics, Inc. : November 24, 2017 Capital Cube
Nov-13-17 12:59PM  ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017 Capital Cube
Nov-10-17 11:31AM  Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe PR Newswire
Nov-07-17 03:10PM  With three products out, Aratana chases its fourth: a canine cancer drug American City Business Journals
08:21AM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-03-17 03:21PM  Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT Thomson Reuters StreetEvents +19.78%
12:26PM  ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017 Capital Cube
06:20AM  Aratana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 06:13PM  Aratana reports 3Q loss Associated Press
04:05PM  Aratana Therapeutics Reports Third Quarter 2017 Financial Results PR Newswire
12:02PM  What Does Aratana Therapeutics Incs (PETX) Share Price Indicate? Simply Wall St.
Oct-30-17 08:30AM  Aratana Therapeutics to Present at Credit Suisse Healthcare Conference PR Newswire
Oct-17-17 09:55AM  ETFs with exposure to Aratana Therapeutics, Inc. : October 17, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics ACCESSWIRE
07:30AM  Corporate News Blog - Aratana Therapeutics Launches ENTYCE (Capromorelin Oral Solution) ACCESSWIRE
Oct-16-17 09:25AM  Hungry for growth, Aratana takes new pet drug to market American City Business Journals
Oct-13-17 04:05PM  Aratana Therapeutics Announces Launch of ENTYCE® (capromorelin oral solution) PR Newswire
Oct-05-17 04:30PM  Aratana Therapeutics to Report Third Quarter 2017 Financial Results PR Newswire +5.01%
Oct-03-17 11:30AM  ETFs with exposure to Aratana Therapeutics, Inc. : October 3, 2017 Capital Cube
Sep-22-17 11:16AM  ETFs with exposure to Aratana Therapeutics, Inc. : September 22, 2017 Capital Cube +5.61%
Sep-18-17 08:00AM  Aratana Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-12-17 12:42AM  ETFs with exposure to Aratana Therapeutics, Inc. : September 12, 2017 Capital Cube
Sep-08-17 04:10PM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 Capital Cube
Aug-13-17 10:50AM  Edited Transcript of PETX earnings conference call or presentation 4-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 03:47PM  Fast 50 CEOs talk about their different paths to rapid growth American City Business Journals
Aug-05-17 01:12AM  Aratana reports 2Q loss Associated Press
Aug-04-17 06:10AM  Investor Network: Aratana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 04:30PM  Aratana Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire
Jul-29-17 06:45AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jul-26-17 03:10PM  Aratana sniffs out new use for dog drug in cats American City Business Journals
08:30AM  Aratana Therapeutics Announces Positive Results for AT-003 PR Newswire
Jul-18-17 04:30PM  Aratana Therapeutics to Report Second Quarter 2017 Financial Results PR Newswire
Jul-07-17 03:22PM  ETFs with exposure to Aratana Therapeutics, Inc. : July 7, 2017 Capital Cube
Jun-26-17 04:40PM  ETFs with exposure to Aratana Therapeutics, Inc. : June 26, 2017 Capital Cube
Jun-16-17 04:11PM  ETFs with exposure to Aratana Therapeutics, Inc. : June 16, 2017 Capital Cube
Jun-14-17 09:35AM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
May-16-17 08:30AM  Aratana Therapeutics to Participate at Three Upcoming Investment Conferences PR Newswire
May-09-17 09:05PM  Edited Transcript of PETX earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
02:40PM  Aratana is tracking to hit canine drug milestone, fetches funds to build inventory American City Business Journals
07:15AM  Investor Network: Aratana Therapeutics, Inc. to Host Earnings Call Accesswire
May-08-17 05:19PM  Aratana reports 1Q loss Associated Press
04:30PM  Aratana Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
May-04-17 09:25AM  Biotech Movers: Aratana Offering Priced Below Market, Shares Fall TheStreet.com
May-03-17 07:29PM  Aratana Therapeutics Announces Pricing of Registered Direct Offering PR Newswire
Apr-25-17 04:30PM  Aratana Therapeutics Provides Update on ENTYCE® PR Newswire
Apr-24-17 08:30AM  Aratana Therapeutics to Report First Quarter 2017 Financial Results PR Newswire
Apr-07-17 05:16PM  ETFs with exposure to Aratana Therapeutics, Inc. : April 7, 2017 Capital Cube
10:15AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) and Lead Plaintiff Deadline - April 7, 2017 Accesswire
03:01AM  DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
Apr-06-17 02:08PM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline of April 7, 2017 Accesswire
Apr-04-17 05:17PM  APRIL 7 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
01:19PM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline of April 7, 2017 Accesswire
11:42AM  DEADLINE FRIDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
10:52AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) and Lead Plaintiff Deadline - April 7, 2017 Accesswire
Apr-03-17 01:12PM  4-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:37AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. - Lead Plaintiff Deadline of April 7, 2017 Accesswire
Mar-31-17 07:33PM  7-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire
05:16PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. - PETX PR Newswire
12:10PM  ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
11:30AM  PETX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Aratana Therapeutics, Inc. and a Lead Plaintiff Deadline of April 7, 2017 GlobeNewswire
Mar-30-17 11:34AM  DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) & Lead Plaintiff Deadline - April 7, 2017 GlobeNewswire
Mar-28-17 06:07PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm Business Wire
12:33PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. Lead Plaintiff Deadline of April 7, 2017 GlobeNewswire
Mar-27-17 04:03PM  ETFs with exposure to Aratana Therapeutics, Inc. : March 27, 2017
01:26PM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
Mar-24-17 07:01PM  Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll Holdings plc, Momenta Pharmaceuticals, Inc., Omnicom Group Inc., Perrigo Company plc, Santander Consumer USA Holdings Inc. and The Interpublic PR Newswire
05:28PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aratana Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline PETX GlobeNewswire
Mar-23-17 01:04PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:50AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aratana Therapeutics, Inc. (PETX) and Lead Plaintiff Deadline - April 7, 2017 Accesswire
Mar-22-17 04:44PM  Why You Should Wait to Buy These 3 Stocks at Motley Fool
11:18AM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:57AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class Action on Behalf of Shareholders of Aratana Therapeutics, Inc. Lead Plaintiff Deadline of April 7, 2017 Business Wire
Mar-21-17 11:41AM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-20-17 12:26PM  READ NOW: Monteverde & Associates PC Invites Aratana Therapeutics, Inc. Shareholders with Losses to Contact the Firm Immediately - PETX Accesswire
10:35AM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-17-17 04:57PM  PETX ALERT: Rosen Law Firm Reminds Aratana Therapeutics, Inc. Investors of Important Deadline in Class Action PETX GlobeNewswire
02:53PM  PETX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Aratana Therapeutics, Inc. and a Lead Plaintiff Deadline of April 7, 2017 Business Wire
01:04PM  ARATANA THERAPEUTICS, INC. Financials
11:26AM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-16-17 09:52AM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
Mar-15-17 09:30AM  Galectin Therapeutics and Aratana Therapeutics Look Forward to the 4th Quarter of 2017 Accesswire
Mar-14-17 05:53PM  Aratana: Osteoarthritis drug for dogs could be a 'blockbuster' at bizjournals.com -23.45%
05:48PM  DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Aratana Therapeutics, Inc. To Contact The Firm Business Wire
02:37PM  Here's Why Aratana Therapeutics Inc. Is Getting Clobbered at Motley Fool
12:56PM  Edited Transcript of PETX earnings conference call or presentation 14-Mar-17 12:30pm GMT
09:26AM  Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira
08:04AM  ARATANA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-13-17 04:44PM  Aratana reports 4Q loss
04:31PM  ARATANA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
04:25PM  Aratana Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
11:30AM  PETX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Aratana Therapeutics, Inc. and a Lead Plaintiff Deadline of April 7, 2017 PR Newswire
10:47AM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the company's licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broadfin Healthcare Master Fun10% OwnerDec 01Sale5.44562,4283,059,3504,294,426Dec 01 05:01 PM
Broadfin Healthcare Master Fun10% OwnerNov 30Sale5.94211,5721,256,5914,856,854Dec 01 05:01 PM
Broadfin Healthcare Master Fun10% OwnerNov 29Sale6.53116,516761,1115,068,426Dec 01 05:01 PM
St Peter StevenPRESIDENT AND CEONov 10Sale7.0050,000350,000529,359Nov 13 06:05 PM
St Peter StevenPRESIDENT AND CEOOct 02Sale6.2450,000312,115579,359Oct 04 06:00 PM
Standridge BrentChief Operating OfficerSep 25Sale6.1110,00061,12770,267Sep 27 06:00 PM
HEINEN ERNSTChief Development OfficerSep 15Sale6.2510,00062,500130,994Sep 19 06:03 PM
St Peter StevenPRESIDENT AND CEOApr 17Option Exercise3.1446,666146,531629,359Apr 18 06:06 PM
St Peter StevenPRESIDENT AND CEOApr 17Sale5.5450,000277,150582,693Apr 18 06:06 PM
St Peter StevenPRESIDENT AND CEOJan 27Sale7.7250,000385,875632,693Jan 31 06:03 PM